Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXELIXIS, INC.EXEL · Entity 3386 | Pres, Prod Dev & Med Aff & CMO | July 26, 2021 | July 29, 2021 |
| GENOCEA BIOSCIENCES, INC.GNCA · Entity 12635 | Director | July 01, 2021 | July 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXELIXIS, INC.
Report date July 26, 2021 · Filed July 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 689,078 |
Reported balance
After 2021-07-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-07-26 · Exercise / conversion · Acquired 40,000 · Balance 689,078 F1: Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.20 · Expires 2023-02-10 | Direct | 0 |
Reported balance
After 2021-07-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-26 · Exercise / conversion · Disposed 40,000 · Balance 0 F3: The option, representing the right to purchase a total of 75,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 14,880 |
Reported balance
Holding disclosure · report date 2021-07-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 14,880 F2: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of July 23, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F2: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of July 23, 2021.
F3: The option, representing the right to purchase a total of 75,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020.
GENOCEA BIOSCIENCES, INC.
Report date July 01, 2021 · Filed July 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.33 · Expires 2031-07-01 | Direct | 15,000 |
Reported balance
After 2021-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-01 · Grant · Acquired 15,000 · Balance 15,000 F1: 100% of the options are scheduled to vest on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the options are scheduled to vest on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2021 Filed Jul 29, 2021 00:06 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0000939767-21-000074 · wf-form4_162751718585473.xml · derivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2023-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 75,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020. Read SEC document |
| July 26, 2021 Filed Jul 29, 2021 00:06 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 40,000 | $4.20 | $168,000.00 |
DisclosureSEC source: 0000939767-21-000074 · wf-form4_162751718585473.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 689,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 23:47 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 35,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0000939767-21-000073 · wf-form4_162708405215652.xml · derivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 35,000 shares Expires 2023-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 75,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 23:47 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 35,000 | $4.20 | $147,000.00 |
DisclosureSEC source: 0000939767-21-000073 · wf-form4_162708405215652.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 11:59 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001457612-21-000084 · wf-form4_162524156338401.xml · derivative · entry 1 Schwab Gisela · CIK 0001213140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: 100% of the options are scheduled to vest on the first anniversary of the grant date. Read SEC document |
| May 13, 2021 Filed May 15, 2021 00:35 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0000939767-21-000050 · wf-form4_162103888892358.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 100,000 shares Expires 2022-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 250,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| May 13, 2021 Filed May 15, 2021 00:35 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 100,000 | $25.38 | $2,538,000.00 |
DisclosureSEC source: 0000939767-21-000050 · wf-form4_162103888892358.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 614,078 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2021. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.15 to $25.65. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| May 13, 2021 Filed May 15, 2021 00:35 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 100,000 | $1.90 | $190,000.00 |
DisclosureSEC source: 0000939767-21-000050 · wf-form4_162103888892358.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 596 shares of common stock acquired on April 30, 2021, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| April 26, 2021 Filed Apr 29, 2021 00:10 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-21-000043 · wf-form4_161965500597259.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 500,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| April 26, 2021 Filed Apr 29, 2021 00:10 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 50,000 | $25.00 | $1,250,000.00 |
DisclosureSEC source: 0000939767-21-000043 · wf-form4_161965500597259.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,482 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2021. Read SEC document |
| April 26, 2021 Filed Apr 29, 2021 00:10 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 50,000 | $1.70 | $85,000.00 |
DisclosureSEC source: 0000939767-21-000043 · wf-form4_161965500597259.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 663,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 23:41 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-21-000039 · wf-form4_161740683370551.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 500,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 23:41 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 50,000 | $23.00 | $1,150,000.00 |
DisclosureSEC source: 0000939767-21-000039 · wf-form4_161740683370551.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,482 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2021. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 23:41 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 50,000 | $1.70 | $85,000.00 |
DisclosureSEC source: 0000939767-21-000039 · wf-form4_161740683370551.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 663,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 04, 2021 Filed Mar 6, 2021 01:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 72,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000035 · wf-form4_161499254775903.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,482 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2022 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 18, 2021 Filed Feb 20, 2021 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-21-000021 · wf-form4_161378260922150.xml · derivative · entry 7 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 50,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 500,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| February 18, 2021 Filed Feb 20, 2021 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 50,000 | $22.35 | $1,117,500.00 |
DisclosureSEC source: 0000939767-21-000021 · wf-form4_161378260922150.xml · nonDerivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,597 Read SEC document |
| February 18, 2021 Filed Feb 20, 2021 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 50,000 | $1.70 | $85,000.00 |
DisclosureSEC source: 0000939767-21-000021 · wf-form4_161378260922150.xml · nonDerivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-21-000021 · wf-form4_161378260922150.xml · derivative · entry 6 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 50,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 500,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 50,000 | $22.50 | $1,125,000.00 |
DisclosureSEC source: 0000939767-21-000021 · wf-form4_161378260922150.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,597 Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 50,000 | $1.70 | $85,000.00 |
DisclosureSEC source: 0000939767-21-000021 · wf-form4_161378260922150.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 171,083 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 01:10 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,858 | $21.91 | $62,618.78 |
DisclosureSEC source: 0000939767-21-000017 · wf-form4_161361060987212.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,597 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved the performance goal on December 4, 2019. F2 · balance_after: Includes 171,083 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 02:16 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 14,982 | $22.56 | $337,993.92 |
DisclosureSEC source: 0000939767-21-000010 · wf-form4_161257775017168.xml · nonDerivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 543,455 F8 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on February 3, 2021. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 02:16 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 71,293 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000010 · wf-form4_161257775017168.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558,437 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F5 · date: On September 20, 2019, the Reporting Person was granted a PSU award the under 2017 Equity Incentive Plan covering 142,586 shares of common stock (such award, the "2019 Award," and such shares, the "Target Shares"). The 2019 Award generally vests as follows: (i) 50% of the Target Shares vest upon the Committee's certification of achievement certain performance criteria as certified by Committee; and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the 2019 Award provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the 2019 Award. F6 · shares: On February 3, 2021, the Committee determined the maximum performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 200% of the Target Shares subject to the 2019 Award. Accordingly, the Committee's certification resulted in the immediate vesting of 25% of the Target Shares, and the remaining 25% of the Target Shares will vest on February 15, 2022, subject to the Reporting Person's continuous service through that date. F7 · balance_after: Includes 178,879 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 02:16 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 9,745 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000010 · wf-form4_161257775017168.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,144 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award under the Exelixis, Inc. 2017 Equity Incentive Plan covering 9,745 shares of common stock (such award, the "2018 Award"). The 2018 Award generally vests as follows: (i) 50% of the original number of shares subject to the 2018 Award vest upon certification by the Compensation Committee (the "Committee") that Exelixis has achieved certain performance criteria related to clinical trial enrollment or positive top-line results (the "2018 Goal"); and (ii) 50% of the original number of shares subject to the 2018 Award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On February 3, 2021, the Committee convened to determine that the 2018 Goal had been achieved, resulting in the immediate vesting of 50% of the 2018 Award, and the remaining 50% will vest on February 15, 2022, subject to the Reporting Person's continuous service through that date. F4 · balance_after: Includes 143,232 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2020 Filed Nov 18, 2020 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,583 | $20.16 | $52,073.28 |
DisclosureSEC source: 0000939767-20-000152 · wf-form4_160566103821240.xml · nonDerivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477,399 F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded on September 22, 2016. Read SEC document |
| November 15, 2020 Filed Nov 18, 2020 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 9,685 | $20.16 | $195,249.60 |
DisclosureSEC source: 0000939767-20-000152 · wf-form4_160566103821240.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479,982 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded on October 3, 2017. Read SEC document |
| November 15, 2020 Filed Nov 18, 2020 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,685 | $20.16 | $54,129.60 |
DisclosureSEC source: 0000939767-20-000152 · wf-form4_160566103821240.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 489,667 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved the performance goal on September 12, 2019. F2 · balance_after: Includes 138,359 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 517 shares of Exelixis, Inc. common stock acquired on October 30, 2020, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| October 22, 2020 Filed Oct 27, 2020 00:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 55,235 | $21.79 | $1,203,570.65 |
DisclosureSEC source: 0000939767-20-000140 · wf-form4_160375744915237.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 491,835 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on October 22, 2020. Read SEC document |
| October 22, 2020 Filed Oct 27, 2020 00:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 213,879 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000140 · wf-form4_160375744915237.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 547,070 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 20, 2019, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 142,586 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the Target Shares vest upon the Committee's certification of achievement certain performance criteria as certified by the Compensation Committee (the "Committee"); and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU. F3 · shares: On October 22, 2020, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 150% of the Target Shares subject to the PSU. Accordingly, the Committee's certification resulted in the immediate vesting of 75% of the Target Shares, and 75% of the Target Shares will vest on November 15, 2021, subject to the Reporting Person's continuous service through that date. The Reporting Person remains eligible for additional vesting depending the level and timing of achievement of the performance criteria through December 31, 2021. F4 · balance_after: Includes 167,307 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 22:32 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,517 | $21.58 | $54,316.86 |
DisclosureSEC source: 0000939767-20-000123 · wf-form4_159925876404670.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,191 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 2, 2020. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 22:32 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 9,745 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000123 · wf-form4_159925876404670.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,708 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award of 9,745 shares of common stock under the Exelixis, Inc. 2017 Equity Incentive Plan. Vesting of the PSU award is tied to performance goals set by the Compensation Committee (the "Committee") as follows: (i) 50% of the original number of shares subject to the award will vest upon the Committee's certification that a target number of potentially label-enabling clinical trials evaluating cabozantinib (both alone or in combination with another therapy) have been initiated; and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On September 2, 2020, the Committee convened to determine that the target number of clinical trial initiations had been achieved, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on November 15, 2021, subject to the Reporting Person's continuous service through that date. F4 · balance_after: Includes 60,367 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| June 04, 2020 Filed Jun 6, 2020 00:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-20-000102 · wf-form4_159140158560171.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 100,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 500,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| June 04, 2020 Filed Jun 6, 2020 00:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 100,000 | $22.96 | $2,296,000.00 |
DisclosureSEC source: 0000939767-20-000102 · wf-form4_159140158560171.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,963 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.47 to $23.46. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| June 04, 2020 Filed Jun 6, 2020 00:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 100,000 | $1.70 | $170,000.00 |
DisclosureSEC source: 0000939767-20-000102 · wf-form4_159140158560171.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 55,494 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 841 shares of common stock acquired on April 30, 2020, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| April 23, 2020 Filed Apr 25, 2020 00:25 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-20-000057 · wf-form4_158777434060565.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 100,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 500,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| April 23, 2020 Filed Apr 25, 2020 00:25 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 100,000 | $26.00 | $2,600,000.00 |
DisclosureSEC source: 0000939767-20-000057 · wf-form4_158777434060565.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,122 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.05. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| April 23, 2020 Filed Apr 25, 2020 00:25 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 100,000 | $1.70 | $170,000.00 |
DisclosureSEC source: 0000939767-20-000057 · wf-form4_158777434060565.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 55,494 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 01:01 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-20-000042 · wf-form4_158354287693678.xml · derivative · entry 5 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 100,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 500,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 01:01 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 50,000 | $19.60 | $980,000.00 |
DisclosureSEC source: 0000939767-20-000042 · wf-form4_158354287693678.xml · nonDerivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,122 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.60 to $19.62. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 01:01 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 50,000 | $19.20 | $960,000.00 |
DisclosureSEC source: 0000939767-20-000042 · wf-form4_158354287693678.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,122 Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 01:01 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 100,000 | $1.70 | $170,000.00 |
DisclosureSEC source: 0000939767-20-000042 · wf-form4_158354287693678.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 55,494 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-20-000025 · wf-form4_158233323874710.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 240,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 40,000 | $21.50 | $860,000.00 |
DisclosureSEC source: 0000939767-20-000025 · wf-form4_158233323874710.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,122 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2020. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 40,000 | $5.51 | $220,400.00 |
DisclosureSEC source: 0000939767-20-000025 · wf-form4_158233323874710.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 55,494 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 16:41 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 9,375 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001457612-20-000020 · wf-form4_158206207720739.xml · derivative · entry 1 Schwab Gisela · CIK 0001213140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 9,375 shares Expires 2030-02-14 F1 · derivative.exercise_date: The stock options vest 33 1/3% on each of February 14, 2021, February 14, 2022, and February 14, 2023 Read SEC document |
| February 07, 2020 Filed Feb 8, 2020 01:43 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-20-000014 · wf-form4_158112617928288.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 50,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 240,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017. Read SEC document |
| February 07, 2020 Filed Feb 8, 2020 01:43 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 50,000 | $18.37 | $918,500.00 |
DisclosureSEC source: 0000939767-20-000014 · wf-form4_158112617928288.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,122 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.14 to $18.62. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| February 07, 2020 Filed Feb 8, 2020 01:43 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 50,000 | $5.51 | $275,500.00 |
DisclosureSEC source: 0000939767-20-000014 · wf-form4_158112617928288.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 55,494 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| January 07, 2020 Filed Jan 10, 2020 01:27 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-20-000002 · wf-form4_157861964149710.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 50,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 240,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.